Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $37,244.78 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 1,882 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $19.79, for a total value of $37,244.78. Following the completion of the transaction, the insider owned 89,324 shares in the company, valued at approximately $1,767,721.96. This trade represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Caroline Baumal also recently made the following trade(s):

• On Thursday, January 22nd, Caroline Baumal sold 2,797 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $21.77, for a total transaction of $60,890.69.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $21.76 on Friday. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $30.91. The firm has a market cap of $2.75 billion, a P/E ratio of 70.18 and a beta of 0.31. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. The business’s 50 day moving average price is $23.02 and its 200 day moving average price is $23.52.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. Apellis Pharmaceuticals’s revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.46) earnings per share. On average, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 207.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after purchasing an additional 19,944 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Apellis Pharmaceuticals by 26.6% in the first quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after buying an additional 64,742 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Apellis Pharmaceuticals by 4.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock worth $4,869,000 after buying an additional 9,747 shares during the last quarter. Focus Partners Wealth lifted its holdings in Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock valued at $479,000 after purchasing an additional 11,862 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Apellis Pharmaceuticals by 1,146.2% in the first quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock valued at $522,000 after purchasing an additional 22,052 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on APLS shares. Wells Fargo & Company reduced their price target on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating on the stock in a research report on Tuesday. Robert W. Baird boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. HC Wainwright cut their price target on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. JPMorgan Chase & Co. cut their target price on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Bank of America raised shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.53.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.